]>
IRCT201210118698N2 IRCT 2012-11-02 Tehran University of Medical Sciences Effect of N-acetylcystein in myocardial infarction Evaluation of N-acetylcystein on biomarkers of platelet activation and coronary reperfusion in patients undergoing percutaneous coronary intervention 2011-01-21 anticipated 100 Complete https://irct.ir/trial/9179 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention. N/A Myocardial Infarction. Intervention 1: The patients in Intervention group were adminitered to take 100 mg/kg Iv bolus N-acetylcystein and then intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary intervention. Intervention 2: Standard regimen for Primary percutaneous coronary intervention (Heparin,Clopidogerel ,ASA ).
public Azita Hajhossein Talasaz, Jamshid Salamzadeh
Tehran Heart Center, Shaheed Beheshti University of Medical Sciences
Tehran Iran (Islamic Republic of) +98 912 377 8707 atalasaz@razi.tums.ac.ir, j.salamzadeh@yahoo.com Tehran Heart Center, Shaheed Beheshti University of Medical Sciences scientific Azita Hajhossein Talasaz, Jamshid Salamzadeh
Jalaal ale ahmad, North karegar
tehran Iran (Islamic Republic of) 1411713138 +91 23778707 atalasaz@razi.tums.ac.ir, j.salamzadeh@yahoo.com Tehran Heart Center, Shaheed Beheshti University of Medical Sciences Iran (Islamic Republic of) Inclusion Criteria:Myocardial infarction patients who were candidate of primary PCI . Exclusion Criteria:rescue pci; emergency for cardiac bypass ; cardiogenic shock; life expactancy less than 6 months; Age less than 18 years old; Uncontrolled hypertension; Thrombocytopenia; Malformation or aneurysm; sever chronic renal failure; Sever liver failure; treatment with glycoprotein IIb/IIIa inhibitors during PCI ; sensitivity to sulfonamides ; Major surjery; Unsatisfactory to enter to study 18 years 90 years Both 121 Acute myocardial infarction Treatment - Drugs Treatment - Drugs The patients in Intervention group were adminitered to take 100 mg/kg Iv bolus N-acetylcystein and then intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary intervention Standard regimen for Primary percutaneous coronary intervention (Heparin,Clopidogerel ,ASA ) IL-10 biomarker of stenosis. Timepoint: after intervention. Method of measurement: Serum concentration ng/ml. TGF-β biomarker of stenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml. CD40L biomarker of restenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml. P-selectin biomarker of restenosis. Timepoint: After intervention. Method of measurement: serum concentration ng/ml. TIMI a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number. MBG a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number. MACE. Timepoint: 30-daye after intervention. Method of measurement: observation. Added at 2014-08-03: Major Adverse cardiac events. Timepoint: Added at 2014-08-03: 30 days and 2 years. Method of measurement: Added at 2014-08-03: call to patient. Tehran University of Medical Sciences Approved 2011-12-13 Tehran heart center North karegar-jalaaal alle ahmad avenue tehran Iran (Islamic Republic of)